Amarin Corp. ADR sell StockNews.com
Start price
05.01.25
/
50%
€0.45
Target price
05.01.26
-
Performance (%)
-21.33%
End price
06.01.26
-
Summary
This prediction is currently being closed. The prediction for Amarin Corp. ADR shows a convincing performance of -21.33%. StockNews_com has a follow-up prediction for Amarin Corp. ADR where he still thinks Amarin Corp. ADR is a Sell. StockNews_com has 50% into this predictionAmarin Corporation plc (Symbol AMRN) is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to improve cardiovascular health. The company's main product, Vascepa, is a prescription medication that has been approved by the US FDA for use as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Vascepa has also shown to reduce the risk of cardiovascular events such as heart attack and stroke in patients with elevated cardiovascular risk. As a listed company, Amarin is publicly traded on the NASDAQ stock exchange and has a market capitalization of approximately $5 billion as of August 2021.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Amarin Corp. ADR | - | - | - |
| iShares Core DAX® | 2.659% | 4.844% | 23.110% |
| iShares Nasdaq 100 | 0.916% | -0.554% | 6.985% |
| iShares Nikkei 225® | 2.426% | 1.598% | 15.780% |
| iShares S&P 500 | 1.230% | 1.039% | 4.695% |
Comments by StockNews_com for this prediction
In the thread Amarin Corp. ADR diskutieren
Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for AMRN provided by MarketBeat
In the thread Trading Amarin Corp. ADR
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten